2000
DOI: 10.1046/j.1365-2257.2000.00258-1.x
|View full text |Cite
|
Sign up to set email alerts
|

Site of subcutaneous desferrioxamine injection is the initial site of post-transfusion urticaria in multi-transfused ββ-thalassaemia major patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2003
2003
2015
2015

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…Concomitant diseases and additional medications were evenly distributed between cases and controls and could not be alleged to be primarily responsible for the elevated ferritin levels (table 1). Regarding the urticaria cases, deferoxamine has been shown to sensitize mast cells around the site of injection, causing a local histamine release [32], and it has been implicated as an allergen in urticarial reactions [33]. However, in the 2 cases with urticaria that were on deferoxamine, we could not implicate this drug in their pathogenesis as both cases subsided without change in the chelation treatment.…”
Section: Discussionmentioning
confidence: 52%
“…Concomitant diseases and additional medications were evenly distributed between cases and controls and could not be alleged to be primarily responsible for the elevated ferritin levels (table 1). Regarding the urticaria cases, deferoxamine has been shown to sensitize mast cells around the site of injection, causing a local histamine release [32], and it has been implicated as an allergen in urticarial reactions [33]. However, in the 2 cases with urticaria that were on deferoxamine, we could not implicate this drug in their pathogenesis as both cases subsided without change in the chelation treatment.…”
Section: Discussionmentioning
confidence: 52%